With 366 million people currently living with diabetes worldwide, this disease constitutes a major public health challenge. Sanofi's aim is to offer all-round therapeutic solutions to patients – medicines, medical devices, services, etc. Among other areas, our research concerns the development of drugs with sustained action or supplied in a combination, the correction of metabolic disorders and their cardiovascular consequences, and a range of different pathological conditions induced by diabetes such as nephropathy, neuropathy, retinopathy, etc.

Sanofi has a strong heritage in oncology research, and notably in chemotherapy. Its aim is to combat cancer in all its different forms by carrying out research on the different pathways involved in the development, growth and propagation of cancer cells. The oncology R&D portfolio contains a range of innovative therapeutic agents with different mechanisms of action. Through collaborations focusing on novel therapeutic approaches, we reinforced our presence in this area.

Over the past 30 years, medical advances have contributed to a significant decline of mortality from cardiovascular diseases. However, cardiovascular diseases still account for the largest number of deaths worldwide, with over 17 million annual deaths, representing 30% of all global death. By 2030, the number of people who die from cardiovascular diseases, mainly from heart disease and strokes, is expected to reach 23.3 million (source: World Health Organization).  Among others, our efforts are on coronary artery disease and heart failure.

In the field of prevention, Sanofi Pasteur is exploring novel technologies and the most recent scientific findings in order to develop safe and effective vaccines with a single or combined target against complex diseases that affect populations throughout the world, such as dengue fever and infections caused by C. difficile. At the same time, our research efforts are focusing on the treatment of multi-resistant hospital-acquired infections, malaria and other parasitic diseases thanks to new antibiotics, antivirals, anti-infective agents and agents that stimulate resistance to infections.

• Learn more on Sanofi Pasteur R&D

Understanding and managing aging-related pathologies and disorders, a field where many medical needs are as yet unmet, are crucial areas for R&D at Sanofi. Treatment of pain, quality of life, independence, the adaptation of pharmaceutical formulations for the elderly or the design of innovative and integrated health solutions are important areas for development in this field.

About 285 million people are visually impaired worldwide: 39 million are blind and 246 million have low vision (source: World Health Organization). Our Ophthalmology Division, Sanofi Fovea, is based in the same building as the Institut de la Vision in Paris, within an ecosystem favoring science translation from bench to bedside, and external innovation. Sanofi Fovea’s portfolio addresses unmet medical needs in pathologies such as retinal degenerative disorders, uveitis, glaucoma and age related macular degeneration.

With Genzyme, we are committed to developing breakthrough therapies for patients who might otherwise have few treatment options; as well as becoming a long term partner to the Multiple Sclerosis community by working to deliver scientific advancements that will have a significant impact on the lives of people living with MS.

• Learn more on: www.genzyme.com
• Discover Genzyme’s interactive MS Atrium on: www.msatrium.com